HM 15275
Alternative Names: HM-15275Latest Information Update: 12 Nov 2024
Price :
$50 *
At a glance
- Originator Hanmi Pharmaceutical
- Class Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Obesity
- Preclinical Heart failure
Most Recent Events
- 06 Nov 2024 Hanmi Pharmaceutical plans phase II trial in Obesity in 2025
- 21 Jun 2024 Preclinical trials in Heart failure in USA (unspecified route), prior to June 2024
- 21 Jun 2024 Pharmacodynamics data from a preclinical studies in Heart failure presented at 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)